XML 64 R51.htm IDEA: XBRL DOCUMENT v3.3.1.900
Revenue Recognition (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Apr. 30, 2014
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Jun. 30, 2015
Revenue Recognition [Line Items]            
Revenue, Net, Total   $ 448,000 $ 7,000 $ 914,000 $ 13,000  
License and Maintenance Revenue       21,000 $ 43,000  
Vyrix Pharmaceuticals Inc [Member]            
Revenue Recognition [Line Items]            
Deferred Revenue $ 250,000          
Deferred Revenue Recognition Period 7 years          
Potential Milestone Payments Receivable $ 3,025,000          
Agreement Expiration Period 15 years          
KOREA | Korean Pharmaceutical Company [Member]            
Revenue Recognition [Line Items]            
Deferred Revenue   500,000   $ 500,000    
Deferred Revenue Recognition Period       10 years 10 years  
KOREA | Ampio [Member]            
Revenue Recognition [Line Items]            
Deferred Revenue           $ 500,000
Deferred Revenue Recognition Period           10 years
Proceeds from License Fees Received           $ 418,000
Potential Milestone Payments Receivable           $ 3,200,000
Percentage Of Royalty Rate Of Net Sales           25.00%
CANADA | Canadian Based Supplier [Member]            
Revenue Recognition [Line Items]            
Deferred Revenue   $ 250,000   $ 250,000    
Deferred Revenue Recognition Period       7 years 7 years